The global helicobacter pylori diagnostics market size was estimated at USD 528.2 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. Increasing demand for personalized antibiotic therapy, rise in infectious diseases, improved cost-effectiveness of diagnosis of helicobacter pylori infection, and rising awareness among people about infections are some of the factors driving the market growth.
Helicobacter pylori (H. pylori) is an aerobic gram-negative bacteria, generally found in the stomach. While it balances the stomach ecology, it can also cause infections in the inner stomach lining. The bacteria can act as one of the causative agents for stomach cancer, duodenal ulcers, gastritis, infection in the small intestine, and gastric ulcers. This has led to an increased demand for diagnostic methods for H. pylori infection. The patients are subject to antibiotic therapy for 10 to 14 days, in case of a positive diagnosis of ulcers caused by H. pylori.
Helicobacter pylori was categorized as a carcinogen in 1994 by the International Agency for Research on Cancer. Although the exact mode of transmission of H. pylori is uncertain, it is suggested that the bacteria infects one individual from another individual through the fecal-oral route. The majority of the patients with H. pylori infection do not demonstrate any specific symptoms, while most of the cases occur in childhood.
Helicobacter pylori infections are particularly prevalent in developing nations. Some of the key factors including the lack of proper water supply, poor sanitation, dense population, and poor personal hygiene can be attributed to the spread of these infections. Rising awareness regarding H. pylori infections in the cohort is one of the factors propelling the market growth. In October 2022, the College of Medicine at Gulf Medical University organized a campaign to spread awareness about H. pylori and related gastric disorders. Such campaigns are expected to increase awareness among people for the prevention of this infection, which is further expected to drive the market.
Easy accessibility and affordability of antibiotics along with short treatment durations can further boost the adoption of antibiotics as well as the demand for pre and post-monitoring tests. Furthermore, the rising incidence of H. pylori infections, the need for early detection of symptoms, and technological advancements in diagnostic techniques are some of the factors driving the market growth.
Based on type, the market is segmented into instruments, reagents, and services. The reagents segment held the largest revenue share in 2022. Moreover, it is anticipated to grow at the fastest CAGR in the forecast period owing to several factors such as the growing incidents of gastric diseases, the need for new technological advancements, and the effectiveness of reagents in the diagnostic process. Reagents are being used in several H. pylori detection tests to detect the presence or absence of the bacteria in the digestive tract. With new test development, this demand for reagents is expected to boost the market growth.
The instruments segment is also anticipated to show lucrative growth over the forecast period owing to their use in hospitals, healthcare centers, and laboratories to detect H. pylori. Instruments such as stool containers are used in stool polymerase chain reaction (PCR) tests, which are performed to detect the bacteria in stool.
In terms of technology, the immunoassay segment held the largest market share in 2022 and is anticipated to lead the market throughout the forecast period. Several advanced technologies such as the enzyme immunoassays are used for the detection of antibodies. Some of the indirect tests include urea breath tests, serology, and rapid urease tests.
Molecular diagnostics held the second-largest market share in 2022. However, molecular diagnostics such as PCR generally offer minimal improvements when carried out through biopsy material. Nevertheless, these tests are particularly beneficial for the precise identification of H. pylori in areas outside the stomach where cultures frequently fail.
In terms of end-user, the hospitals segment held the largest market share of 46.9% in 2022 due to the ease of disease presentation, accessibility of doctors, and the rising prevalence of diseases such as duodenal ulcers, stomach cancer, gastritis and gastric ulcers, and infections to the small intestine. According to the Pan America Health Organization (PAHO), in 2019, digestive disorders accounted for 37.2 deaths per 1,00,000 populations across the region.
The diagnostic laboratories segment is expected to grow at the fastest CAGR of 5.1% during the forecast period. More specialized and efficient infection detection along with rising awareness regarding infectious diseases are the key factors responsible for the favorable growth.
Based on region, North America held the largest revenue share of 40.1 % in 2022, which is attributed to the development of healthcare infrastructure; initiatives by organizations such as CDC, FDA, and NIH; and the presence of developed economies.
Latin America is anticipated to grow at the fastest CAGR of 6.4% in the forecast period owing to the rising importance to the healthcare sector, increasing infectious diseases prevalence, and awareness. According to an article published by Science Direct in July 2022, Latin America is ranked second in incidents of gastric cancer.
Companies are adopting various strategies such as new product development, mergers and acquisitions, strategic partnerships, and regional expansions to gain a competitive advantage. In May 2022, Biomerica, a biomedical technology company, announced the CE Mark for hp+detect. It is a diagnostic test that detects H. pylori. The company is expected to sell the diagnostic test in the European Union and other nations following the registration of its product in the respective countries.
In April 2021, Otsuka Pharmaceutical Cop, Ltd. launched QuickNavi, a kit for quick detection of H. pylori. It can provide test results in eight minutes. In October 2018, DiaSorin S.p.A collaboration with Meridian Bioscience, Inc. to sell DiaSorin’s FDA-approved stool agent test to detect H. pylori. Some prominent players in the global Helicobacter pylori diagnostics market include:
Thermo Fisher Scientific
Quest Diagnostics Incorporated
Alpha Laboratories Ltd
F. Hoffmann-La Roche Ltd
Epitope Diagnostics, Inc.
Market size value in 2023
USD 555.95 million
Revenue forecast in 2030
USD 757.84 million
CAGR of 4.5% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, technology, end-user, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait;
Key companies profiled
Thermo Fisher Scientific; Biohit Oyj; Quest Diagnostics Incorporated; Meridian Bioscience; Bio-Rad Laboratories; Alpha Laboratories Ltd; F. Hoffmann-La Roche Ltd; Coris BioConcept; Certest Biotec; Epitope Diagnostics, Inc.;
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Helicobacter pylori diagnostics market report based on type, technology, end-user, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Technology Outlook (Revenue, USD Million, 2018 - 2030)
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global helicobacter pylori diagnostics market size was estimated at USD 528.2 million in 2022 and is expected to reach USD 555.9 million in 2023.
b. The global helicobacter pylori diagnostics market is expected to grow at a compound annual growth rate of 4.5% from 2023 to 2030 to reach USD 757.8 million by 2030.
b. North America dominated the helicobacter pylori diagnostics market with a share of 40.0% in 2022. This is attributable to increasing healthcare expenditure, favorable reimbursement scenarios, and the presence of major players in the region.
b. Some key players operating in the helicobacter pylori diagnostics market include Thermo Fisher Scientific, Biohit, Quest Diagnostics, Meridian Bioscience, Bio-Rad Laboratories, Alpha Laboratories, F. Hoffmann-La Roche, Coris BioConcept, Certest Biotec, and Epitope Diagnostics.
b. Key factors that are driving the market growth include increasing demand for personalized antibiotic therapy and improving cost-effectiveness of diagnosis of helicobacter pylori infection.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."